Investor Presentaiton
R&D milestones in 2019
Investor presentation
Full year 2018
Slide 15
Project
TresibaⓇ
OzempicⓇ
Anti-IL-21
LAI287
LAIsema
Oral semaglutide
Amylin - AM833
GG-co-agonist
Tri-agonist 1706
PYY 1562
N8-GP
Concizumab
Q1 2019
US submission
US submission
(CV label update)
Q2 2019
Phase 3b results
(vs glargine U300)
Phase 2 results
Clinical milestones1
Regulatory milestones¹
Q3 2019
Q4 2019
Phase 2 results
Phase 1 initiation
Phase 1 results
Phase 3b CVOT initiation
EU submission
US regulatory decision
Japan submission
Phase 2 initiation
Phase 1 results
US regulatory decision
EU regulatory decision
Phase 1 results
Phase 1 results
Japan regulatory decision
Somapacitan
Diabetes
Obesity
Haemophilia
Phase 3 initiation
Phase 3 initiation
(GHD)
US and EU submission
(AGHD)
Growth disorders
1 Expected to be published in the given quarter or in the subsequent quarterly company announcement
GHD: Growth hormone deficiency; AGHD: Adult growth hormone deficiency; CVOT: cardiovascular outcomes trial
Japan submission
(AGHD)View entire presentation